Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants
Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants
調査の概要
詳細な説明
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Aichi、日本、451-0052
- GSK Investigational Site
-
Chiba、日本、275-8580
- GSK Investigational Site
-
Fukuoka、日本、802-8533
- GSK Investigational Site
-
Hiroshima、日本、720-8520
- GSK Investigational Site
-
Hiroshima、日本、734-8530
- GSK Investigational Site
-
Hiroshima、日本、737-0811
- GSK Investigational Site
-
Hiroshima、日本、730-8518
- GSK Investigational Site
-
Hiroshima、日本、730-8798
- GSK Investigational Site
-
Hokkaido、日本、065-0033
- GSK Investigational Site
-
Hokkaido、日本、003-0021
- GSK Investigational Site
-
Kagawa、日本、765-8501
- GSK Investigational Site
-
Kanagawa、日本、247-8533
- GSK Investigational Site
-
Miyagi、日本、983-8520
- GSK Investigational Site
-
Miyagi、日本、981-3203
- GSK Investigational Site
-
Nagano、日本、386-8610
- GSK Investigational Site
-
Nagasaki、日本、856-8562
- GSK Investigational Site
-
Niigata、日本、957-8588
- GSK Investigational Site
-
Okayama、日本、701-1192
- GSK Investigational Site
-
Okayama、日本、701-0204
- GSK Investigational Site
-
Osaka、日本、591-8025
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of age at the time of the first vaccination.
- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Written informed consent obtained from the parent or guardian of the subject.
- Born between a gestation period of 36 and 42 weeks inclusive.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.
- History of use of experimental rotavirus vaccine.
- Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusception.
- Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition determined by the investigator.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Previous confirmed occurrence of RV GE.
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).
- A family history of congenital or hereditary immunodeficiency.
- Acute disease at the time of enrolment.
- Gastroenteritis within 7 days preceding the study vaccine administration.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Rotarix Group
Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
|
Two-dose oral vaccination.
|
|
プラセボコンパレーター:Placebo Group
Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
|
Two-dose oral administration.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
時間枠:From 2 weeks after Dose 2 up to 2 years of age
|
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
|
From 2 weeks after Dose 2 up to 2 years of age
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
時間枠:From 2 weeks after Dose 2 up to 2 years of age
|
A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).
|
From 2 weeks after Dose 2 up to 2 years of age
|
|
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type
時間枠:From 2 weeks after Dose 2 up to 2 years of age
|
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode. Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system). |
From 2 weeks after Dose 2 up to 2 years of age
|
|
Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types
時間枠:From 2 weeks after Dose 2 up to 2 years of age
|
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode. Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system). |
From 2 weeks after Dose 2 up to 2 years of age
|
|
Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains
時間枠:From 2 weeks after Dose 2 up to 2 years of age
|
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
|
From 2 weeks after Dose 2 up to 2 years of age
|
|
Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains
時間枠:From Dose 1 up to 2 years of age
|
Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode. Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system). |
From Dose 1 up to 2 years of age
|
|
Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration
時間枠:2 months after Dose 2
|
Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs).
Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).
|
2 months after Dose 2
|
|
Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies
時間枠:2 months after Dose 2
|
Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e.
prior to the first dose of rotarix) seronegative.
|
2 months after Dose 2
|
|
Number of Subjects Reporting Solicited Symptoms
時間枠:During the 8-day follow-up period after each dose
|
Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.
|
During the 8-day follow-up period after each dose
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
時間枠:During the 31-day follow-up period after each dose
|
Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
During the 31-day follow-up period after each dose
|
|
Number of Subjects Reporting Serious Adverse Events (SAEs)
時間枠:Up to 2 years of age
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
Up to 2 years of age
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Buyse H, Vinals C, Karkada N, Han HH. The human rotavirus vaccine Rotarix in infants: an integrated analysis of safety and reactogenicity. Hum Vaccin Immunother. 2014;10(1):19-24. doi: 10.4161/hv.26476. Epub 2013 Oct 8.
- Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011 Aug 26;29(37):6335-41. doi: 10.1016/j.vaccine.2011.05.017. Epub 2011 Jun 2.
- Kawamura N et al. Efficacy of Human Rotavirus (G1P[8] strain) Vaccine (HRV) RIX4414 in Japanese Infants during the Two-year Efficacy Follow-up Period. Abstract presented at the 114th Annual Meeting of Japan Pediatric Society (JPS). Tokyo, Japan, 12-14 August 2011.
- Kawamura N et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. Abstract presented at the 28th meeting of European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010.
- Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N, Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021 Nov 17;11(11):CD008521. doi: 10.1002/14651858.CD008521.pub6.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 107625
- 2015-001543-36 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
試験データ・資料
-
インフォームド コンセント フォーム
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
統計分析計画
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
個人参加者データセット
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
研究プロトコル
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
データセット仕様
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
注釈付き症例報告書
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
臨床研究報告書
情報識別子:107625情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。